We developed a naringenin–hesperidin molar mixture (MIX–160) with proven antihyperglycemic and vasorelaxant activity in preclinical studies. A solid dosage form was manufactured to improve the bioavailability properties. In current study, we sought evaluate oral toxicity of MIX–160 form, which showed no mortality or significant changes body weight, food consumption tissue/organ mass rats. Three...